Reuters logo
BRIEF-Pharnext announces DSMB recommends continuing the ongoing Phase 3 trial of PXT3003
September 6, 2017 / 3:55 PM / 3 months ago

BRIEF-Pharnext announces DSMB recommends continuing the ongoing Phase 3 trial of PXT3003

Sept 6 (Reuters) - PHARNEXT SAS:

* ANNOUNCES THAT THE DSMB RECOMMENDS CONTINUING THE ONGOING PHASE 3 TRIAL OF PXT3003 FOR CHARCOT-MARIE-TOOTH DISEASE TYPE 1A

* WE LOOK FORWARD TO COMPLETING THIS CLINICAL TRIAL AND SHARING TOP-LINE RESULTS IN MID-2018 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below